Supplemental Table 1 - Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease

Name: Supplemental Table 1 - Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease
Creator: Tarun Sontam
Published: 2025-05-19T17:53:29.835Z
Keywords: Stroke, Ischemic Heart Disease, Peripheral Arterial Disease, Psoriasis

Sontam, Tarun; Chen, Helen; Raman, Justin; Chen, Aaron; Cho, Seo Won; Tarbox, Michelle

doi:10.17632/ghkf6y44x9.2

Supplemental Table 1 - Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease

Published: 19 May 2025| Version 2 | DOI: 10.17632/ghkf6y44x9.2

Contributors:

Tarun Sontam, Helen Chen, Justin Raman, Aaron Chen, Seo Won Cho, Michelle Tarbox

Description

Supplemental Table 1. Baseline characteristics of GLP1-RA cohort and GLP1-RA-naïve cohort before and after propensity-score matching (PSM). Bold standard difference indicates standard difference (std diff) > 0.1.

Supplemental Table 1 - Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease

Description

Files

Categories

Licence